FDA recently approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Value to improve therapy options for individuals with mitral or aortic valve disease.
The next-generation devices...
AstraZeneca and VaxEquity recently collaborated to discover, develop, and commercialize a self-amplifying RNA (saRNA) therapeutics platform.
The long-term research collaboration aims to optimize...
Roche recently announced that Tecentriq elicited disease-free survival in patients with Stage II-IIA non-small cell lung cancer (NSCLC).
Data from the IMpower010 trial, published in The Lancet, found...
Thermo Fisher Scientific recently launched the integrated Gibco AAV-MAX Helper Free AAV Production System to enable scalable gene therapy workflows.
The solution aims to simplify AAV vector production...
AbbVie and Regenxbio recently partnered to develop and commercialize RGX-314, a potential one-time gene therapy to treat various chronic retinal diseases.
Researchers are currently evaluating...
Johnson & Johnson recently announced that its Ebola vaccine regimen, Zabdeno and Mvabea, generated robust antibody immune responses in children and adults.
The Phase 3 EBOVAC-Salone clinical...
FDA recently granted Breakthrough Designation for Eli Lilly & Company and Boehringer Ingelheim’s diabetes drug, Jardiance, as an investigational treatment for adults with heart failure with...
Pfizer recently initiated a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus (RSV) vaccine candidate in adults.
The...
Medidata and Labcorp Drug Development recently entered into an agreement to expand decentralized clinical trial capabilities and digital biomarker discovery.
The companies will leverage Medidata...
Eli Lilly and Company recently announced that its prescription medicine, Jardiance, elicited a 21-percent relative risk reduction in death or hospitalization for heart failure patients compared to...
Thermo Fisher Scientific and AstraZeneca recently entered into a global, multiyear partnership to co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) for targeted...
Black Americans are still significantly underrepresented in cardiovascular disease clinical trials, and enrollment rates have not improved over time, according to a new paper published in the Journal...
Eli Lilly and Company recently entered into a multi-year research collaboration and licensing agreement with Lycia Therapeutics to discover, deliver, and commercialize novel targeted drug...
Merck recently announced that its pneumococcal 15-valent conjugate vaccine, Vaxneuvance, met key immunogenicity and safety endpoints in a Phase 3 clinical trial.
The PNEU-PED study enrolled...
Johnson & Johnson recently announced that a booster dose of its COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after...
Novartis recently announced that the Phase 3 clinical trial investigating its aggressive B-cell-non-Hodgkin lymphoma (NHL) treatment, Kymriah, did not meet its primary endpoint of event-free survival...
Bristol Myers Squibb recently announced that FDA accepted a supplemental biologics license application for its Acute Graft Versus Host Disease (aGvHD) therapy, Orencia.
Orencia is intended to...
AstraZeneca recently announced that its COVID-19 antibody combination, AZD442, reduced the risk of symptomatic coronavirus by 77 percent compared to placebo in a Phase 3 trial.
The randomized,...
GoodRx and Boehringer Ingelheim recently collaborated to increase affordable drug access for patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD).
Under the...
